Bellefleur has been acquired by Domidep
Belgian nursing home Bellefleur has been sold to Domidep, one of France’s largest private nursing home operators.
Headquartered in Aubange, Belgium, Bellefleur owns and operates a state-of-the-art nursing home in the Luxembourg province. After the nursing home’s refurbishment and extension in 2022, Bellefleur operates 91 accredited beds, with a total capacity for 99 beds. Through its strategic location, a limited competitive landscape in the region and efficient management, Bellefleur has been able to achieve an occupancy rate of around 100% for long-term stays since 2022.
Founded in 1989, Domidep is a leading player in the healthcare sector, operating mainly medicalized nursing homes. On the strength of its roots and experience in France, with almost 120 establishments at the end of 2022 accommodating 7,700 residents, Domidep is now also expanding internationally. The company is already present in Germany and Belgium, with over 35 establishments for almost 2,900 residents.
Oaklins’ team in Belgium acted as the exclusive M&A sell-side advisor to Bellefleur in this transaction.
Talk to the deal team
Laurent Wielfaert
Oaklins KBC Securities
Related deals
Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
Learn moreCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Learn morePanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production
PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.
Learn more